Opinion
Video
Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer
Author(s):
Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.
EP: 1.Challenges in Diagnosing HER2+ Breast Cancer
EP: 2.Neoadjuvant Treatment Options in HER2+ Early Breast Cancer
EP: 3.Preoperative Monitoring and Surgical Options for HER2+ Patients
Now Viewing
EP: 4.Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer
EP: 5.Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC
EP: 6.Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer
EP: 7.Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets
EP: 8.Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges
EP: 9.Overview of DESTINY-Breast06
EP: 10.Clinical Perspectives on Managing ILD Related to T-DXd
EP: 11.Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC
EP: 12.Unmet Needs and Future Direction in HER2+ Breast Cancer
Video content above is prompted by the following question(s):
- What is your institution’s approach to utilizing subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase vs. intravenous pertuzumab and trastuzumab in the neoadjuvant and adjuvant setting?
Related Videos
Related Content
